PŘEHLEDOVÉ ČLÁNKY Problematika antibiotické léčby u pacientů s covidem-19 454 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék 2021; 67(8): 448–454 / www.casopisvnitrnilekarstvi.cz 9. Chen N, Zhou M, Dong X et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507–513. Dostupné z DOI: < https://doi.org/10.1016/S0140-6736(20)30211-7>. 10. Nori P, Cowman K, Chen V, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. Infect Control Hosp Epidemiol 2021; 42(1): 84–88. Dostupné z DOI: <https://doi.org/10.1017/ice.2020.368>. 11. Lansbury L, LimB, Baskaran V, LimWS. Co‑infections in people with COVID-19: a systema‑ tic review and meta‑analysis. J Infect 2020; 81(2): 266–275. Dostupné z DOI: < https://doi.or‑ g/10.1016/j.jinf.2020. 05. 046>. 12. Vaughn VM, Gandhi T, Petty LA et al. Empiric Antibacterial Therapy and Community‑onset Bacterial Co‑infection in Patients Hospitalizedwith COVID-19: AMulti‑Hospital Cohort Study. Clin Infect Dis 2021; 72(10): e533–e541. Dostupné z DOI: < https://doi.org/10.1093/cid/ciaa1239>. 13. Buetti N, Mazzuchelli T, Lo Priore E et al. Early administered antibiotics do not impact mor‑ tality in critically ill patients with COVID-19. J Infect 2020; 81(2): e148–e149. Dostupné z DOI: <https://doi.org/10.1016/j.jinf.2020. 06. 004>. 14. Garcia‑Vidal C, Sanjuan G, Moreno‑García E et al. Incidence of co‑infections and super‑ infections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Micro‑ biol Infect 2021; 27(1): 83–88. Dostupné z DOI: < https://doi.org/10.1016/j.cmi.2020. 07. 041>. 15. Chedid M, Waked R, Haddad E et al. Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy. J Infect Public Health 2021; 14(5): 570–576. Dostupné z DOI: < https://doi.org/10.1016/j.jiph.2021. 02. 001>. 16. Wang D, Hu B, Hu C et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061–1069. Dopstupné z DOI: <https://doi.org/10.1001/jama.2020.1585>. 17. Wang D, Yin Y, Hu C et al. Clinical course and outcome of 107 patients infectedwith the no‑ vel coronavirus, SARS‑CoV-2, discharged from two hospitals in Wuhan, China. Crit Care 2020; 24(1): 188. Dostupné z DOI: < https://doi.org/10.1186/s13054-020-02895-6>. 18. Wang Z, Yang B, Li Q et al. Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis 2020; 71(15): 769–777. Dostupné z DOI: <https://doi.org/10.1093/ cid/ciaa272>. 19. He Y, Li W, Wang Z, et al. Nosocomial infection among patients with COVID-19: a retro‑ spective data analysis of 918 cases from a single center inWuhan, China. Infect Control Hosp Epidemiol 2020; 41(8): 982–983. Dostupné z DOI: <https://doi.org/10.1017/ice.2020.126>. 20. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coro‑ navirus in Wuhan, China. Lancet 2020; 395(10223): 497–506. Dostupné z DOI: <https://doi. org/10.1016/S0140-6736(20)30183-5>. 21. Chen G, Wu D, Guo W et al. Clinical and immunological features of severe and modera‑ te coronavirus disease 2019. J Clin Invest 2020; 130(5): 2620–2629. Dostupné z DOI: <https:// doi.org/10.1172/JCI137244>. 22. Chen T, Wu D, Chen H et al. Clinical characteristics of 113 deceased patients with coro‑ navirus disease 2019: retrospective study. BMJ 2020; 368: m1295. Dostupné z DOI: <https:// doi.org/10.1136/bmj.m1295>. 23. Chen H, Guo J, Wang C et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medi‑ cal records Lancet 2020; 395 (10226): 809–815. Dostupné z DOI: <https://doi.org/10.1016/ S0140-6736(20)30360-3>. 24. Xu XW, Wu XX, Jiang XG et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS‑Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020; 368: m606. Dostupné z DOI: <https://doi.org/10.1136/bmj.m606>. 25. Cao B, Wang Y, Wen D et al. A trial of Lopinavir–Ritonavir in adults hospitalizedwith severe Covid-19. N Engl J Med 2020; 382(19): 1787–1799. Dostupné z DOI: <https://doi.org/10.1056/ NEJMoa2001282>. 26. Zhao XY, Xu XX, Yin HS et al. Clinical characteristics of patients with 2019 coronavirus di‑ sease in a non‑Wuhan area of Hubei Province, China: a retrospective study. BMC Infect Dis 2020; 20(1): 311. Dostupné z DOI: <https://doi.org/10.1186/s12879-020-05010-w>. 27. Borba MGS, Val FFA, Sampaio VS et al. Effect of high vs low doses of chloroquine diphos‑ phate as adjunctive therapy for patients hospitalized with severe acute respiratory syndro‑ me coronavirus 2 (SARS‑CoV-2) infection: a randomized clinical trial. JAMA NetwOpen 2020; 3(4): e208857. Dostupné z DOI: <https://doi.org/10.1001/jamanetworkopen.2020.8857>. 28. Pedersen HP, Hildebrandt T, Poulsen A, et al. Initial experiences from patients with CO‑ VID-19 on ventilatory support in Denmark. DanMed J 2020; 67(5): A04200232. PMID: 32351196. 29. Aggarwal S, Garcia‑Telles N, Aggarwal G et al. Clinical features, laboratory characteris‑ tics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Ear‑ ly report from the United States. Diagnosis 2020; 7(2): 91–96. Dostupné z DOI: <https://doi. org/10.1515/dx-2020-0046>. 30. GuanW, Ni Z, Hu Y et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382(18): 1708–1720. Dostupné z DOI: <https://doi.org/10.1056/NEJMoa2002032>. 31. Htoutou Sedláková M, Vojtová V, Hanulík V, et al. Rezistence enterobakterií k vybraným antibiotikům v souvislosti s jejich spotřebou. Klin Farmakol Farm 2012; 26(2): 61–66. 32. Urbanek K, Kolar M, Loveckova Y et al. Influence of 3rd generation cephalosporin utili‑ zation on the occurrence of ESBL‑positive Klebsiella pneumoniae strains. J Clin Pharm Ther 2007; 32(4): 403–408. Dostupné z DOI: <https://doi.org/10.1111/j.1365-2710.2007.00836.x>. 33. Kolar M, Urbanek K, Latal T. Antibiotic selective pressure and development of bacte‑ rial resistance. Int J Antimicrob Agents 2001; 17(5): 357–363. Dostupné z DOI: <https://doi. org/10.1016/s0924-8579(01)00317-x>. 34. KimHS. Do an altered gut microbiota and an associated leaky gut affect COVID-19 seve‑ rity? mBio 2021; 12 (1): e03022-20. Dostupné z DOI: <https://doi.org/10.1128/mBio.03022-20>. 35. Martin E, Philbin M, Hughes G et al. Antimicrobial stewardship challenges and innova‑ tive initiatives in the acute hospital setting during the COVID-19 pandemic. J Antimicrob Chemother 2021; 76(1): 272–275. Dostupné z DOI: <https://doi.org/10.1093/jac/dkaa400>. 36. Sieswerda E, De Boer MGJ, Bonten MM et al. Recommendations for antibacterial thera‑ py in adults with COVID-19 – An evidence based guideline. Clin Microbiol Infect 2021; 27(1): 61–66. Dostupné z DOI: <https://doi.org/10.1016/j.cmi.2020. 09. 041>. 37. World Health Organization. COVID-19 Clinical management: living guidance. WHO. [cit. 2021-09-01]. Dostupné z WWW: <https://www.who.int/publications/i/item/WHO-2019nCoV‑clinical-2021-1>. 38. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing CO‑ VID-19. NICE. [cit. 2021-09-01]. Dostupné zWWW: <https://www.nice.org.uk/guidance/ng191>. 39. Cong W, Poudel AN, Alhusein N et al. Antimicrobial Use in COVID-19 Patients in the First Phase of the SARS‑CoV-2 Pandemic: A Scoping Review. Antibiotics 2021; 10(6): 745. Dostup‑ né z DOI: <https://doi.org/10.3390/antibiotics10060745>. 40. Liu C, Wen Y, Wan W et al. Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19. Int Immunopharmacol 2021; 90: 107157. Dostup‑ né z DOI: <https://doi.org/10.1016/j.intimp.2020.107157>. 41. Kolář M. Respirační infekce a jejich léčba. Maxdorf: Praha 2016. ISBN 978-80-7345-481-4. 42. Kolář M, Bardoň J, Rejman D. Zásady antibiotické léčby. VUP: Olomouc 2020. ISBN 978-80-244-5740-6. 43. Kolář M, Beneš J, Kolek V, et al. Klinický doporučený postup Nozokomiální pneumonie – antibiotická léčba. Národní portál klinických doporučených postupů [cit. 2021-09-01]. Do‑ stupné z WWW: <https://kdp.uzis.cz>. 44. Torres A, NiedermanM, Chastre J et al. International ERS/ESICM/ESCMID/ALAT guidelines for themanagement of hospital‑acquired pneumonia and ventilator‑associated pneumonia. Eur Respir J 2017; 50(3): 1700582. Dostupné z DOI: <https://doi.org/10.1183/13993003.005822017>.
RkJQdWJsaXNoZXIy NDA4Mjc=